Objectives: The objectives of this presentation is to examine the physician perspective of having HUDs for our patients.

Introduction: Home Use Devices (HUDs) have become commonplace around the globe for patients interested in doing home treatments in the aesthetic space either alone or as adjunctive therapy from health care providers. What was once felt that these devices would “hurt” physician visits and take away from potential income from medical personal has truly not been the case.

Materials / method: HUDs can be an entry way for patients to begin the rejuvenation or hair removal process for some, and many have used these products to compliment what we, as providers do, in our office settings.

Results: New and exciting HUDs are emerging into the global marketplace and we will review these and how they are changing the HUD landscape.

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作的完成感谢以下机构的支持： The Home Use Device Working Group.

Objectives: This session will explore the evolving role of low-level light therapy (LLLT) and photobiomodulation in promoting hair growth, emphasizing mechanisms, efficacy, and integration into clinical practice. Special attention will be given to the interplay of light-based therapies with wound healing processes and potential to enhance follicular regeneration. Emerging home-based devices, which empower patients to manage hair loss, will also be discussed with emphasis on design, safety, and evidence-based outcomes.

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

Objectives: To raise the awareness of professional bodies and national regulators of possible non-compliance with the EU Medical Device Regulations (EU MDR) of some home-use devices being sold with potential safety risks to consumers.

Introduction: EU MDR Implementing Regulations were published in December 2022 and June 2023 regarding transitional provisions for certain products without an intended medical purpose. During this time there was a high influx of devices with minimal safety features. From the implementation date of transitional provisions, industry observers have noted the appearance in the market of new devices and/or significant changes in existing devices not permitted under regulations. The Transitional Provisions need to be enforced by the European Commission to ensure safety standards are maintained.

Materials / method: There is disparity between current published standards and the industry standard used by established European manufacturers. This includes the requirement for skin tone sensors and clinical safety and performance studies.

The industry standard also includes the Common Specifications requirement for ‘full skin contact’ versus ‘good contact with the skin’ in the current EN standard, where there is an increased risk of eye exposure from intense light flashing in free space.

Results: APPLiA, the Brussels-based trade association for European home appliance manufacturers, is concerned that these safety features are not standard in newly introduced devices as this is not required by legislation until the end of the transition period in 2028. Examples have been found of possible non-compliances.

Conclusion: Support is needed from national regulators to enforce EU MDR Transitional Provisions, and safety features should be explained to consumers. APPLiA has published a white paper to reach out to authorities and other professional bodies for support and to actively explain safety features to consumers.

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

Objectives: Several clinical studies of the photodynamic treatment of actinic keratosis and actinic cheilitis demonstrated that White LED photodynamic therapy(PDT) is a valuable alternative to conventional PDT performed with red light with better tolerability (almost painless) and lack of inferior efficacy. In addition, White LED illumination seems to present practical advantages in comparison with outdoor daylight PDT because the spectrum and light dose are fixed and reproducible and it is always feasible and programmable regardless of weather and environmental problems.

Materials / method: Fronville M, Creusot M, Mordon SR. Is a 4 J/cm2 PpIX-Weighted Simulated Daylight (SDL-PDT) Dose Still Efficient for Photodynamic Therapy of Actinic Keratosis? Pharmaceuticals (Basel). 2023 Oct 13;16(10):1454.
Arisi M, Rossi MT, Spiazzi L, Guasco Pisani E, Venturuzzo A, Rovati C, Tomasi C, Venturini M, Calzavara-Pinton PG. A randomized split-face clinical trial of conventional vs indoor-daylight photodynamic therapy for the treatment of multiple actinic keratosis of the face and scalp and photoaging. J Dermatolog Treat. 2022 Jun;33(4):2250-2256.

Results: Arisi M, Galli B, Pisani EG, La Rosa G, Licata G, Rovaris S, Tomasi C, Rossi M, Venturini M, Spiazzi L, Calzavara-Pinton P. Randomized Clinical Trial of Conventional versus Indoor Daylight Photodynamic Therapy for Treatment of Actinic Cheilitis. Dermatol Ther (Heidelb). 2022 Sep;12(9):2049-2061.
Creusot M, Mordon S. Clinical evaluation of a short illumination duration (1 hour) when performing photodynamic therapy of actinic keratosis using the Dermaris light source. Photodiagnosis Photodyn Ther. 2021 Dec;36:102618

Conclusion: Maire C, Vignion-Dewalle AS, Cartier H, Mordon S. Artificial white light photodynamic therapy for actinic keratosis: a study of 38 patients in private office practice. J Eur Acad Dermatol Venereol. 2020 Apr;34(4):e165-e167.

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。